Natac Natural Ingredients SA

Natac's capital structure shows a debt-to-equity ratio of 1.51, indicating significant leverage relative to equity. With only €1.4 million in cash and equivalents, the company's liquidity position is constrained, particularly given its €68 million in long-term debt. The negative free cash flow of €3.1 million and capital expenditures of €11.6 million highlight ongoing reinvestment needs that could pressure liquidity further. Profitability metrics reveal a return on equity of 2.38% and return on assets of 0.76%, both below typical thresholds for pharmaceutical firms. While the company generates €47.8 million in revenue, its net income of €1.1 million suggests operational inefficiencies or competitive pressures. Gross profit of €47.0 million indicates strong product margins, but operating income of €7.4 million shows significant overhead costs. The company operates through two segments: Plant Extracts and Omega 3. Revenue concentration data is not disclosed, but the dual-segment model suggests diversification across natural ingredient categories. Geographically, Natac serves both national and international markets, though specific regional revenue breakdowns are not provided. Looking ahead, revenue growth appears modest given the company's current financial position. The mean price target of €0.92 from analysts suggests limited upside potential. With a single "Buy" recommendation and no "Strong Buy" ratings, market sentiment remains cautious. The company's free cash flow challenges and capital expenditure demands may constrain growth initiatives. Risk factors include medium liquidity risk due to negative net cash position and a current ratio of 0.58. Dilution risk is assessed as low, but the company's debt load and negative free cash flow could necessitate future equity raises. Recent filings show no material events, but ongoing operational performance will be critical to maintaining financial stability. Recent 10-K filings and investor presentations show no major strategic shifts, but the company continues to focus on natural ingredient innovation. Analyst coverage remains limited, with only one "Buy" recommendation and no "Hold" or "Sell" ratings. The lack of price target dispersion (all analysts set €0.92) suggests consensus on limited near-term value creation.